SCHEDULE: Cadian Capital Discloses 7.7% Stake in MaxCyte

Cadian Capital Management and affiliates report a 7.7% beneficial ownership stake in MaxCyte, Inc., holding over 8.2 million shares.

Summary

• Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
• The Reporting Persons beneficially own 8,227,603 shares of MaxCyte, Inc. Common Stock.
• This ownership represents approximately 7.7% of MaxCyte, Inc.'s outstanding Common Stock.
• The percentage is based on 106,644,343 shares of Common Stock outstanding as of September 30, 2025, as disclosed in MaxCyte's Form 10-Q filed on November 13, 2025.
• The shares are held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, advisory clients of Cadian Capital Management, LP.
• Cadian Capital Management, LP exercises exclusive voting and investment power over these securities.
• Cadian Master Fund L.P. individually directly holds Common Stock representing more than 5% of the Issuer's Common Stock.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of MaxCyte, Inc.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.

Positives

• A significant institutional investor, Cadian Capital Management, maintains a substantial stake, potentially indicating confidence in MaxCyte's long-term prospects.

Negatives

• The filing itself does not contain specific negative financial or operational information about MaxCyte, Inc.

Risks

• The filing does not detail specific risks related to MaxCyte, Inc.'s operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding MaxCyte, Inc.'s future performance or outlook.

Industry Context

This filing reflects an institutional investor's significant stake in MaxCyte, Inc., a company operating in the biotechnology sector. Such disclosures are common and provide transparency regarding major shareholders, which can influence market perception and investor confidence within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market sentiment and potentially provide a degree of stability or scrutiny.

Key Dates

Keywords

MaxCyte Inc., Cadian Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, Biotechnology